Merrill Lynch analyst Geoff Meacham reiterated a Buy rating on Bristol Myers Squibb on Monday, setting a price target of $80, which is approximately 36.24% above the present share price of $58.72.
Meacham expects Bristol Myers Squibb to post earnings per share (EPS) of -$0.04 for the fourth quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in Bristol Myers, with an average price target of $71.5.
The analysts price targets range from a high of $80 to a low of $64.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $10.13 billion and a net profit of $891 million. The company's market cap is $132.35 billion.
According to TipRanks.com, Merrill Lynch analyst Geoff Meacham is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.3% and a 56.84% success rate.
Bristol-Myers Squibb (NYSE:BMY) Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.